BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 17943974)

  • 1. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
    Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
    Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR.
    Jin L; Lloyd RV; Nassar A; Lappinga PJ; Sebo TJ; Swartz K; Seys AR; Erickson-Johnson MR; Roth CW; Evers BR; Oliveira AM; Zhang J
    Diagn Mol Pathol; 2011 Jun; 20(2):71-80. PubMed ID: 21532495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.
    Chiappetta G; Ferraro A; Vuttariello E; Monaco M; Galdiero F; De Simone V; Califano D; Pallante P; Botti G; Pezzullo L; Pierantoni GM; Santoro M; Fusco A
    Eur J Cancer; 2008 May; 44(7):1015-21. PubMed ID: 18375116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
    Lappinga PJ; Kip NS; Jin L; Lloyd RV; Henry MR; Zhang J; Nassar A
    Cancer Cytopathol; 2010 Oct; 118(5):287-97. PubMed ID: 20597139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling.
    Zhao J; Leonard C; Gemsenjäger E; Heitz PU; Moch H; Odermatt B
    Oncol Rep; 2008 Feb; 19(2):329-37. PubMed ID: 18202778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A link between the expression of the stem cell marker HMGA2, grading, and the fusion CRTC1-MAML2 in mucoepidermoid carcinoma.
    Fehr A; Meyer A; Heidorn K; Röser K; Löning T; Bullerdiek J
    Genes Chromosomes Cancer; 2009 Sep; 48(9):777-85. PubMed ID: 19521953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
    Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
    Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
    Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
    Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
    Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
    Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
    Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGA2 overexpression in non-small cell lung cancer.
    Meyer B; Loeschke S; Schultze A; Weigel T; Sandkamp M; Goldmann T; Vollmer E; Bullerdiek J
    Mol Carcinog; 2007 Jul; 46(7):503-11. PubMed ID: 17477356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ECM1 expression in thyroid tumors--a comparison of real-time RT-PCR and IHC.
    Lal G; Padmanabha L; Nicholson R; Smith BJ; Zhang L; Howe JR; Robinson RA; O'Dorisio MS
    J Surg Res; 2008 Sep; 149(1):62-8. PubMed ID: 18374945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours.
    Franco R; Esposito F; Fedele M; Liguori G; Pierantoni GM; Botti G; Tramontano D; Fusco A; Chieffi P
    J Pathol; 2008 Jan; 214(1):58-64. PubMed ID: 17935122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.
    Rosen J; He M; Umbricht C; Alexander HR; Dackiw AP; Zeiger MA; Libutti SK
    Surgery; 2005 Dec; 138(6):1050-6; discussion 1056-7. PubMed ID: 16360390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms.
    Nagar S; Ahmed S; Peeples C; Urban N; Boura J; Thibodeau B; Akervall J; Wilson G; Long G; Czako P
    Am J Surg; 2014 Apr; 207(4):596-601. PubMed ID: 24713092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; McMillan A
    Cancer; 2006 Jun; 106(12):2592-7. PubMed ID: 16688775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?
    Letsas KP; Vartholomatos G; Tsepi C; Tsatsoulis A; Frangou-Lazaridis M
    Neoplasma; 2007; 54(1):57-62. PubMed ID: 17203893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.